Can airway cell clues predict a rare lung disease in children?
NCT ID NCT06140901
First seen Aug 03, 2026 · Last updated Aug 04, 2026 · Updated 1 time
Summary
This study looks at children aged 1 month to 6 years who are hospitalized with a severe respiratory infection caused by adenovirus or rhinovirus. The goal is to compare the airway cells of those who develop a rare lung condition called post-infectious bronchiolitis obliterans (PIBO) with those who do not. Researchers will collect nasal samples and, in children who develop PIBO, also take bronchial biopsies and washings to examine the cells' shape and function. The hope is to understand why some children get PIBO and to find early signs that could lead to faster diagnosis.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Nasal swab and brushing, bronchial biopsies, and bronchoalveolar lavage (diagnostic procedures)
- What this could lead to
- If successful, this could help identify early markers that predict which children with adenovirus or rhinovirus infections will develop bronchiolitis obliterans, potentially leading to earlier diagnosis and better management.
- What could go wrong
- This is a small pilot study, so findings may not be definitive or generalizable. The procedures are invasive and carry risks, and the study does not test a treatment, so it may not directly change patient care.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 450 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
Dec 2023
- Expected to finish
-
Aug 2027
An estimate. End dates often move.
- Lead sponsor
-
A government agency
The lead sponsor is a government body.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
1 month to 6 years
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Children from 1 month to 6 years hospitalized at the Timone Enfant University Hospital 2. Diagnosis of an adenovirus or rhinovirus respiratory infection confirmed on a nasal swab, made upon arrival as part of the child's initial care 3. Consent form read, understood, approved and signed by parents before any study procedure 4. Affiliation to a social security scheme or beneficiary of such a scheme The inclusion criteria for children who were not hospitalized when diagnosed with an adenovirus and rhinovirus respiratory infection at the Timone Enfant University Hospital are: 1. Children from 1 month to 6 years old transferred to the Timone Enfant University Hospital 2. Show the following signs: has. Clinical: clinical signs persist 6 weeks after a viral infection: tachypnea, wheezing and/or persistent hypoxemia b. Scan: mosaic appearance +/- bronchiectasis, atelectasis vs. +/- EFR if performed: obstructive ventilatory disorder not or only slightly reversible after bronchodilators 3. Consent form read, understood, approved and signed by parents before any study procedure 4. Affiliation to a social security scheme or beneficiary of such a scheme Exclusion Criteria: 1. Refusal of participation in the study by the family will be a reason for non-inclusion, as well as in the absence of parental authority. 2. The existence of an underlying chronic pulmonary pathology (e.g. cystic fibrosis, ciliary dyskinesia). 3. A coagulation pathology.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bronchiolitis obliterans are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
APHM
RECRUITINGMarseille, 13000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New study aims to detect lung damage earlier in young transplant patients
- Can lung MRI replace CT scans for detecting a serious Post-Transplant lung condition?
- Inhaled drug aims to save transplanted lungs from silent threat
- New hope for lung scarring after transplant: belumosudil trial launches
- Inhaled cyclosporine aims to halt lung transplant rejection
- Lung transplant infection study aims to improve Long-Term survival